These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 23662843)

  • 21. Does enzyme replacement therapy improve symptoms of Fabry disease in patients undergoing dialysis?
    Banikazemi M; Desnick RJ
    Nat Clin Pract Nephrol; 2006 Feb; 2(2):72-3. PubMed ID: 16932395
    [No Abstract]   [Full Text] [Related]  

  • 22. Enzyme replacement in Anderson-Fabry disease.
    Bengtsson BA; Johansson JO; Hollak C; Linthorst G; FeldtRasmussen U
    Lancet; 2003 Jan; 361(9354):352. PubMed ID: 12559898
    [No Abstract]   [Full Text] [Related]  

  • 23. Immune response to enzyme replacement therapy in Fabry disease: impact on clinical outcome?
    Hollak CE; Linthorst GE
    Mol Genet Metab; 2009 Jan; 96(1):1-3. PubMed ID: 19062323
    [No Abstract]   [Full Text] [Related]  

  • 24. Fabry disease: clinical outcomes of agalsidase enzyme replacement therapies.
    Wanner C
    Int J Clin Pract; 2007 Jul; 61(7):1234-5; author reply 1235. PubMed ID: 17577304
    [No Abstract]   [Full Text] [Related]  

  • 25. Reduction in ECG abnormalities and improvement of regional left ventricular function in a patient with Fabry's disease during enzyme-replacement therapy.
    Prinz C; Farr M; Hering D; Horstkotte D; Faber L
    Clin Res Cardiol; 2010 Jan; 99(1):53-5. PubMed ID: 19774328
    [No Abstract]   [Full Text] [Related]  

  • 26. [Utility of enzyme replacement therapy in Fabry disease].
    Politei JM; Dubrovsky A
    Med Clin (Barc); 2010 Apr; 134(9):402-5. PubMed ID: 20138313
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enzyme replacement therapy and Fabry kidney disease: quo vadis?
    Warnock DG
    J Am Soc Nephrol; 2007 May; 18(5):1368-70. PubMed ID: 17429046
    [No Abstract]   [Full Text] [Related]  

  • 28. Fabry disease.
    Thomas AS; Hughes DA
    Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():88-101. PubMed ID: 25345090
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fabry disease: the need to stratify patient populations to better understand the outcome of enzyme replacement therapy.
    Germain DP
    Clin Ther; 2007; 29 Suppl A():S17-8. PubMed ID: 17580237
    [No Abstract]   [Full Text] [Related]  

  • 30. Young woman with recurrent ischemic strokes diagnosed as Fabry disease: lessons learned from a case report.
    Zenone T; Chan V
    Clin Neurol Neurosurg; 2011 Sep; 113(7):586-8. PubMed ID: 21420783
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enzyme replacement in the treatment of Fabry's disease. Is there a point-of-no-return?
    del Toro N; Milán JA; Palma A
    Nephrol Dial Transplant; 2004 Apr; 19(4):1018. PubMed ID: 15031378
    [No Abstract]   [Full Text] [Related]  

  • 32. Enzyme replacement therapy with agalsidase alfa in pregnant women with Fabry disease.
    Kalkum G; Macchiella D; Reinke J; Kölbl H; Beck M
    Eur J Obstet Gynecol Reprod Biol; 2009 May; 144(1):92-3. PubMed ID: 19233535
    [No Abstract]   [Full Text] [Related]  

  • 33. Differences in cleavage of globotriaosylceramide and its derivatives accumulated in organs of young Fabry mice following enzyme replacement therapy.
    Kodama T; Tsukimura T; Kawashima I; Sato A; Sakuraba H; Togawa T
    Mol Genet Metab; 2017; 120(1-2):116-120. PubMed ID: 27756537
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adaptive pathway development for Fabry disease: a clinical approach.
    Schuller Y; Arends M; Körver S; Langeveld M; Hollak CEM
    Drug Discov Today; 2018 Jun; 23(6):1251-1257. PubMed ID: 29455022
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Schiffmann R, Rapkiewicz A, Abu-Asab M, Ries M, Askari H, Tsokos M, Quezado M. Pathological findings in a patient with Fabry disease, who died after 2.5 years of enzyme replacement. Virchows Arch. 2005 Nov 29; 1-7.
    Politei J
    Virchows Arch; 2006 Jun; 448(6):873. PubMed ID: 16523259
    [No Abstract]   [Full Text] [Related]  

  • 36. Electron-microscopy of cherry haemangioma in the early diagnosis of Fabry disease.
    Tokuriki A; Kiyohara T; Kumakiri M
    Acta Derm Venereol; 2013 Jul; 93(4):471-2. PubMed ID: 23138542
    [No Abstract]   [Full Text] [Related]  

  • 37. [Efficacy of replacement enzyme therapy on central nervous system manifestations in Fabry's disease].
    Besson G; Vadot W; Guellerin J
    Rev Med Interne; 2010 Dec; 31 Suppl 2():S257-9. PubMed ID: 21211675
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of a chemically modified plant cell culture expressed human α-Galactosidase-A enzyme for treatment of Fabry disease.
    Kizhner T; Azulay Y; Hainrichson M; Tekoah Y; Arvatz G; Shulman A; Ruderfer I; Aviezer D; Shaaltiel Y
    Mol Genet Metab; 2015 Feb; 114(2):259-67. PubMed ID: 25155442
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful desensitization to agalsidase beta after anaphylaxis.
    Talreja N; Butt A; Valle RL; Fox RW; Lockey RF
    Ann Allergy Asthma Immunol; 2014 Jan; 112(1):71-2. PubMed ID: 24331397
    [No Abstract]   [Full Text] [Related]  

  • 40. Liquid chromatography-tandem mass spectrometry quantification of globotriaosylceramide in plasma for long-term monitoring of Fabry patients treated with enzyme replacement therapy.
    Roddy TP; Nelson BC; Sung CC; Araghi S; Wilkens D; Zhang XK; Thomas JJ; Richards SM
    Clin Chem; 2005 Jan; 51(1):237-40. PubMed ID: 15514097
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.